Trial Profile
Observational trial to assess the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 04 Jun 2019 Preliminary results (n=200) published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Interim results (n=176) presented at the 54th Annual Meeting of the American Society of Clinical Oncology